Processa Pharmaceuticals, Inc. – NASDAQ:PCSA
Processa Pharmaceuticals stock price today
Processa Pharmaceuticals stock price monthly change
Processa Pharmaceuticals stock price quarterly change
Processa Pharmaceuticals stock price yearly change
Processa Pharmaceuticals key metrics
Market Cap | 2.71M |
Enterprise value | 772.80K |
P/E | -0.28 |
EV/Sales | N/A |
EV/EBITDA | -0.05 |
Price/Sales | N/A |
Price/Book | 0.94 |
PEG ratio | N/A |
EPS | -0.58 |
Revenue | N/A |
EBITDA | -12.97M |
Income | -9.82M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProcessa Pharmaceuticals stock price history
Processa Pharmaceuticals stock forecast
Processa Pharmaceuticals financial statements
| Jun 2023 | 0 | -2.61M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.08M | |
| Dec 2023 | 0 | -2.40M | |
| Mar 2024 | 0 | -2.72M |
| Mar 2024 | 0 | -2.72M | |
|---|---|---|---|
| Sep 2025 | 0 | -578.7K | |
| Oct 2025 | 0 | -11.09M | |
| Dec 2025 | 0 | -11.09M |
Analysts Price target
Financials & Ratios estimates
| 2023-05-18 | -0.28 | -0.2 |
|---|
| Jun 2023 | 10090423 | 930.74K | 9.22% |
|---|---|---|---|
| Sep 2023 | 8082726 | 914.84K | 11.32% |
| Dec 2023 | 5786643 | 797.48K | 13.78% |
| Mar 2024 | 9944732 | 1.06M | 10.67% |
| Jun 2023 | -2.06M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -1.76M | -2.77K | -52.74K |
| Dec 2023 | -2.12M | 0 | -30.60K |
| Mar 2024 | -2.04M | 0 | 6.26M |
Processa Pharmaceuticals alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
Processa Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 80000 | 0 |
| Jun 2023 | 40000 | 0 |
| Jan 2024 | 20500 | 0 |
| Feb 2024 | 42500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | YOUNG DAVID director, officer.. | Common Stock | 21,000 | $2.45 | $51,534 | ||
Purchase | YOUNG DAVID director, officer.. | Common Stock | 20,000 | $2.53 | $50,500 | ||
Purchase | LIN PATRICK officer: Chief Bu.. | Common Stock | 1,500 | $2.4 | $3,600 | ||
Purchase | LIN PATRICK officer: Chief Bu.. | Common Stock | 2,500 | $2.37 | $5,925 | ||
Purchase | NG GEORGE K director, officer: Chief Execut.. | Common Stock | 10,000 | $2.7 | $27,000 | ||
Purchase | YORKE JUSTIN W director | Common Stock | 8,000 | $2.69 | $21,544 | ||
Option | NEAL JAMES R director | Common Stock | 14,407 | N/A | N/A | ||
Option | NEAL JAMES R director | Common Stock | 14,407 | N/A | N/A | ||
Option | NEAL JAMES R director | Common Stock | 14,407 | N/A | N/A | ||
Option | NEAL JAMES R director | Restricted Stock | 14,407 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q4 2022 31 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 12 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 14 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 14 May 2022 | Q1 2022 Earnings Call Transcript |
-
What's the price of Processa Pharmaceuticals stock today?
One share of Processa Pharmaceuticals stock can currently be purchased for approximately $0.21.
-
When is Processa Pharmaceuticals's next earnings date?
Unfortunately, Processa Pharmaceuticals's (PCSA) next earnings date is currently unknown.
-
Does Processa Pharmaceuticals pay dividends?
No, Processa Pharmaceuticals does not pay dividends.
-
How much money does Processa Pharmaceuticals make?
Processa Pharmaceuticals has a market capitalization of 2.71M. Processa Pharmaceuticals made a loss 11.12M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.
-
What is Processa Pharmaceuticals's stock symbol?
Processa Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PCSA".
-
What is Processa Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Processa Pharmaceuticals?
Shares of Processa Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Processa Pharmaceuticals's key executives?
Processa Pharmaceuticals's management team includes the following people:
- Dr. Sian E. Bigora Ph.D., Pharm.D. Co-Founder & Chief Devel. Officer(age: 65, pay: $100,460)
- Mr. Robert Michael Floyd Chief Operating Officer(age: 69, pay: $98,980)
- Mr. Patrick Lin Co-Founder, Chief Bus. & Strategy Officer(age: 60, pay: $96,180)
- Ms. Wendy J. Guy Co-Founder, Chief Admin. Officer & Corporation Sec.(age: 61, pay: $88,410)
- Mr. James H. Stanker Chief Financial Officer(age: 67, pay: $87,500)
- Dr. David Young Ph.D., Pharm.D. Co-Founder, Chairman, Interim Chief Financial Officer & Chief Executive Officer(age: 72, pay: $58,330)
-
Is Processa Pharmaceuticals founder-led company?
Yes, Processa Pharmaceuticals is a company led by its founders Dr. Sian E. Bigora Ph.D., Pharm.D., Mr. Patrick Lin, Ms. Wendy J. Guy and Dr. David Young Ph.D., Pharm.D..
-
How many employees does Processa Pharmaceuticals have?
As Jul 2024, Processa Pharmaceuticals employs 13 workers, which is 13% less then previous quarter.
-
When Processa Pharmaceuticals went public?
Processa Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 7 Mar 2014.
-
What is Processa Pharmaceuticals's official website?
The official website for Processa Pharmaceuticals is processapharmaceuticals.com.
-
Where are Processa Pharmaceuticals's headquarters?
Processa Pharmaceuticals is headquartered at 7380 Coca Cola Drive, Hanover, MD.
-
How can i contact Processa Pharmaceuticals?
Processa Pharmaceuticals's mailing address is 7380 Coca Cola Drive, Hanover, MD and company can be reached via phone at +44 37763133.
Processa Pharmaceuticals company profile:
Processa Pharmaceuticals, Inc.
processapharmaceuticals.comNASDAQ
13
Biotechnology
Healthcare
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Hanover, MD 21076
CIK: 0001533743
ISIN: US74275C3043
CUSIP: 74275C205
